COMPASS Pathways (NASDAQ: CMPS ) shares are up during Tuesday’s premarket session following the company’s announcement of achieving the primary endpoint in its Phase 3 COMP006 trial for treatment-resistant depression .
Depression Data
The company reported that in the 25 mg arm of its trial, there was a statistically significant reduction in symptom severity for treatment-resistant depression.
In COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001).
Clinically meaningful reduction in MADRS (≥ 25%) observed in a significant number of participants in the 25mg arm of both trials, with 25% in COMP005 and 39% in COMP006, a proprietary formulation of psilocybin.
Additionally, the data suggest that COMP360 is generally well-tolerated, with most treatment-emergent adverse events being mild or moderate. The company is advancing discussions with the FDA to submit a New Drug Application (NDA) in Q4 2026, which could pave the way for new treatment options in a space with limited alternatives.
In June 2025, COMPASS Pathways shared data from the Phase 3 COMP005 trial. A single dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity compared to placebo .
Technical Analysis
Currently, the stock is trading 31.15% above its 12-month performance, reflecting strong momentum.
The shares are positioned closer to their 52-week highs than lows, indicating bullish sentiment among investors.
The RSI is at a neutral level, while the MACD is below its signal line, suggesting bearish pressure on the stock. This combination indicates mixed momentum, as the stock has not yet established a clear trend direction.
Key Resistance: $8.00 Key Support: $6.00Analyst Consensus & Recent Actions
The stock carries a Buy rating with an average price target of $18.15. Recent analyst moves include:
RBC Capital: Outperform (Raises Target to $21) Morgan Stanley: Overweight (Raises Target to $11) BTIG: Buy (Raises Target to $14)Top ETF Exposure
ADVISORSHARES PSYCHEDELICS ETF (NYSE: PSIL ): 8.62% WeightCMPS Price Action: Compass Pathways shares were up 23.06% at $7.15 during premarket trading on Tuesday, according to Benzinga Pro data .
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Biotech News Health Care Top Stories Movers General benzai why it's moving